Physician profile
Robert A Feldman
NPI 1053394205
$10,394.69
in general payments reported to CMS, 2019-2025
31 companies · $82.08 in 2025
The $82.08 reported for 2025 was less than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,469 · 2020: $183 · 2021: $464 · 2022: $307 · 2023: $592 · 2024: $1,297 · 2025: $82.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,024 · Food and Beverage: $854 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,024.00 |
| Food and Beverage | $853.62 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $5,538.48 | 2019 | |
| Pfizer INC. | $1,786.22 | 2019-2024 | |
| Sanofi Pasteur INC. | $1,024.00 | 2024 | |
| Abbvie INC. | $671.71 | 2019-2024 | |
| Astellas Pharma US INC | $220.04 | 2023-2024 | Veozah |
| Mayne Pharma Commercial LLC | $124.46 | 2023 | |
| Therapeuticsmd, INC. | $120.14 | 2019-2022 | |
| Exact Sciences Corporation | $105.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Myovant Sciences INC. | $97.85 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $94.60 | 2019-2020 | |
| Hologic Sales and Service, LLC | $76.95 | 2021-2024 | Aptima, Thinprep 2000 Processor |
| Vertical Pharmaceuticals, LLC | $69.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.38 | 2019-2025 | |
| Millicent US INC | $43.13 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Avion Pharmaceuticals | $41.57 | 2019-2023 | Balcoltra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $40.55 | 2023-2024 | Slynd |
| Sumitomo Pharma America, INC. | $39.33 | 2023-2024 | Myfembree |
| Allergan, INC. | $38.21 | 2019-2020 | |
| Lupin INC. | $30.20 | 2019 | |
| Virtus Pharmaceuticals LLC | $24.41 | 2021 | |
| Mylan Pharmaceuticals INC. | $23.04 | 2022 | |
| Agile Therapeutics, INC. | $22.23 | 2021 | |
| Roche Diagnostics Corporation | $19.52 | 2021 | |
| Evofem Biosciences, INC. | $17.50 | 2024 | |
| Ascend Therapeutics US, LLC | $16.89 | 2021 | |
| Eisai INC. | $15.74 | 2021 | |
| Mission Pharmacal Company | $15.63 | 2021 | |
| Coopersurgical, INC. | $14.33 | 2025 | Paragard T 380a |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.